Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2005

View Archived Issues

New oxazolinone-based uPA inhibitor with potential in cancer therapy

New phase III data on the efficacy of fesoterodine in OAB

First results on the efficacy and safety of EG-005 in lipodystrophy

Good safety profile reported for CTLA4-Ig in multiple sclerosis

AVP-923 improves pseudobulbar affect in patients with MS

Withdrawal of European marketing authorizations for Venvia/Nyracta

Kentera begins European roll-out

Enrollment begins in phase III alfimeprase study for acute PAO

AVI BioPharma presents positive data from studies on NeuGene antisense technology

Roche will not pursue MEM-1414, MEM-1917 in Memory collaboration

Ranexa meets primary endpoint in ERICA study

Novel voltage-sensitive sodium channel blockers with activity against human prostate cancer

Clavis Pharma presents promising oral alternative to gemcitabine

Cellegy submits Cellegesic written response

Novel G-quadruplex DNA motif-targeting agent nearing human testing

AP-23573 receives fast track designation for soft tissue and bone sarcomas

Early clinical results for Clavis Pharma's lead development candidate

New European approval for InductOs

Antiviral effects of a novel nonimmunosuppressive ciclosporin analogue

Chugai, Mitsui and CIEA create Forerunner Pharma Research

Intendis opens new Japanese subsidiary

Inflazyme charts progress from preclinical company

Effects of ospemifene and raloxifene compared in postmenopausal women

Abciximab evaluated in acute ischemic stroke

JSW-Research claims new agents for CNS degenerative disorders

Neurocrine reports new agents for gynecological disorders

New antismoking therapy developed by Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...